Long-Term Survival Probability in Men with Clinically Localized Prostate Cancer

	Tweet

Randomized studies comparing conservative therapy to definitive therapy in men with prostate cancer (CaP) are underway, but not yet available. Dr. Tewari and associates used the Henry Ford database to analyze the outcomes of 3,159 men treated either conservatively or with radiotherapy or radical prostatectomy (RP) in the years 1980 to 1997. Their report suggesting superior outcomes for active treatment appears in Urology.

Participants were younger than 75 years and had socioeconomic, clinical, pathological and demographic data reviewed. Men with positive bones scans were excluded. The primary endpoint was death from all causes and the secondary endpoint was death from CaP. Radiotherapy or RP had to be received by the patient within 6 months of diagnosis.

The treatment characteristics revealed that 42% were treated conservatively, 28% received radiotherapy and 30% underwent RP. Patients who underwent RP were younger and healthier (by Charlson scores). Both radiotherapy and RP men had more aggressive tumor histology. Patients from 1980 to 1990 were more likely to be treated conservatively than patients seem after 1990 (59% vs. 30%). An equal proportion of black and white men were treated conservatively, but more blacks underwent radiotherapy. Surgery patients tended to be white and live in an area of higher income.

Surgery reduced the 15-year mortality rate by 59% overall and by 47%, 60%, and 65% for men with grade 1, 2, and 3 tumors, respectively. The overall survival advantage was 8.6 years and was 6.8, 5.5, and 10.4 years for patients with grade 1, 2, and 3 disease, respectively. Radiotherapy patients also experienced a survival advantage with a reduction in mortality of 33%. The survival advantage was also found for CaP-specific survival. Radiotherapy or RP reduced the death rate from CaP by 38% and 63%, respectively, compared with patients treated conservatively. Overall, but not cancer-specific mortality correlated with Charlson index scores.

The reduction in mortality was greatest in patients with poorly differentiated CaP undergoing surgery, but decreases in death occurred in all subsets of patients undergoing definitive treatment. Referee pathologic review was not performed, although all pathology was interpreted at the single institution.

Tewari A, Raman JD, Chang P, Rao S, Divine G, Menon M

Urol 2006;68(6):1268-74

By Christopher P. Evans, MD

Source: UroToday

RELATED STORIES:
Should the UK lower the age for prostate cancer detection?   Noninvasive prostate treatment developed   Prostate cancer clinical stage does not predict recurrence   New research sheds light on gene destruction linked to aggressive prostate cancer   Scientists Find Second Site for Prostate Cancer Gene   Freezing prostate cancer does a man’s body good   Turmeric holds real potential for the treatment and prevention of prostate cancer   Black men least likely to get prostate cancer screening even during peak ages of risk   Heavy men fare poorly with prostate cancer   Prostate cancer therapy linked to increased risk of heart disease death   Acquisition of Robotic Technology Leads to Increased Rates of Prostate Cancer Surgery   Carcinoma of the Prostate Treatment   Scientists discover way to block growth of prostate cancer cells   Prostate cancer cost varies widely by treatment   Castrate resistant prostate cancer: New therapeutic approaches   Age alone should not be used to determine whether to treat prostate cancer with hormones   Swiss study finds income affects prostate cancer patients’ survival   Mushroom extract may boost prostate cancer drug   Fat intake increases prostate cancer risk   Innovation and current status of prostate cancer gene therapy featured in Human Gene Therapy   No link seen between coffee, prostate cancer risk   ARRA Funds Research to Improve Prostate Cancer Identification

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]